

| |
|---|
| TRADEMARK ASSIGNMENT COVER SHEET |
|---|

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM550381

| | |
|------------------------------|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | Amended and Restated Intellectual Property Security Agreement |

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|----------------|----------|----------------|--|
| Harrow IP, LLC | | 11/14/2019 | Limited Liability Company: DELAWARE |

RECEIVING PARTY DATA

| | |
|------------------------|--------------------------------------|
| Name: | SWK Funding LLC, as Collateral Agent |
| Street Address: | 14755 Preston Road, Suite 105 |
| City: | Dallas |
| State/Country: | TEXAS |
| Postal Code: | 75254 |
| Entity Type: | Limited Liability Company: DELAWARE |

PROPERTY NUMBERS Total: 55

| Property Type | Number | Word Mark |
|-----------------------------|---------|---------------------------|
| Registration Number: | 5470969 | |
| Registration Number: | 5747816 | BRIM-DOR |
| Registration Number: | 5158156 | COMBINATION DROP THERAPY |
| Registration Number: | 5293114 | CORRECT COMPOUND |
| Registration Number: | 5025348 | DEFEAT IC |
| Registration Number: | 5131504 | DEX-MOXI |
| Registration Number: | 5587077 | DEX-MOXI-KETOR |
| Registration Number: | 5125985 | DROPLESS |
| Registration Number: | 5423725 | DROP-LESS |
| Registration Number: | 5018511 | DROPLESS CATARACT SURGERY |
| Registration Number: | 4978985 | DROPLESS CATARACT THERAPY |
| Registration Number: | 4884290 | DROPLESS THERAPY |
| Registration Number: | 4976595 | ED FREE |
| Registration Number: | 4958892 | ED FREE |
| Registration Number: | 5562939 | GATI-DEX |
| Registration Number: | 5022923 | GO DROPLESS |
| Registration Number: | 4972265 | GO DROPLESS |
| Registration Number: | 4950925 | GODROPLESS |
| Registration Number: | 4938331 | HLA |

TRADEMARK

| Property Type | Number | Word Mark |
|----------------------|----------|--------------------------|
| Registration Number: | 5100697 | IMPRIMIS |
| Registration Number: | 4890492 | IMPRIMIS |
| Registration Number: | 5008088 | IMPRIMIS CARES |
| Registration Number: | 5022193 | IMPRIMIS CARES! |
| Registration Number: | 4978131 | IMPRIMIS PHARMACEUTICALS |
| Registration Number: | 4890493 | IMPRIMISRX |
| Registration Number: | 5163172 | IV FREE |
| Registration Number: | 5198496 | IV FREE |
| Registration Number: | 5662585 | KLARITY DROPS |
| Registration Number: | 5681626 | KLARITY-C DROPS |
| Registration Number: | 5091225 | LESS DROPS |
| Registration Number: | 4884291 | LESSDROPS |
| Registration Number: | 4950904 | LESSDROPS |
| Serial Number: | 87799283 | MELT |
| Registration Number: | 5158235 | MKO MELT |
| Registration Number: | 5134795 | PPS-DR |
| Registration Number: | 5577593 | PRED-BROM |
| Registration Number: | 5342159 | PRED-GATI |
| Registration Number: | 5505056 | PRED-GATI-BROM |
| Registration Number: | 5342160 | PRED-GATI-NEPAF |
| Registration Number: | 5117425 | PRED-KETOR |
| Registration Number: | 5039133 | PRED-MOXI |
| Registration Number: | 5117424 | PRED-MOXI-KETOR |
| Registration Number: | 5342161 | PRED-NEPAF |
| Registration Number: | 5716196 | SIMPLE DROPS |
| Registration Number: | 5688871 | SIMPLE DROPS |
| Registration Number: | 4919401 | SSP TECHNOLOGY |
| Registration Number: | 5438639 | STERICHECK |
| Registration Number: | 5505057 | TIM-BRIM-DOR |
| Registration Number: | 5505058 | TIM-BRIM-DOR-LAT |
| Registration Number: | 5505062 | TIM-DOR-LAT |
| Registration Number: | 5542813 | TIM-LAT |
| Registration Number: | 5638938 | TOTAL TEARS |
| Registration Number: | 5565048 | TOTAL TEARS |
| Registration Number: | 5034588 | TRI-MOXI |
| Registration Number: | 5083870 | TRIPLE DROP |

CORRESPONDENCE DATA

**TRADEMARK
REEL: 006800 FRAME: 0942**

Fax Number: 2138918763

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: rhonda.deleon@lw.com

Correspondent Name: Latham & Watkins LLP

Address Line 1: 355 South Grand Avenue

Address Line 4: Los Angeles, CALIFORNIA 90071-1560

| | |
|--------------------------------|-------------|
| ATTORNEY DOCKET NUMBER: | 060232-0001 |
|--------------------------------|-------------|

| | |
|---------------------------|---------------|
| NAME OF SUBMITTER: | Rhonda DeLeon |
|---------------------------|---------------|

| | |
|-------------------|-----------------|
| SIGNATURE: | /Rhonda DeLeon/ |
|-------------------|-----------------|

| | |
|---------------------|------------|
| DATE SIGNED: | 11/21/2019 |
|---------------------|------------|

Total Attachments: 14

source=Imprimis - AR Intellectual Property Security Agreement Executed#page1.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page2.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page3.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page4.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page5.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page6.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page7.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page8.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page9.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page10.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page11.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page12.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page13.tif
source=Imprimis - AR Intellectual Property Security Agreement Executed#page14.tif

AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT (“Agreement”) dated as of November 14, 2019, is made by HARROW HEALTH, INC. (f/k/a Imprimis Pharmaceuticals, Inc.), a Delaware corporation (“Harrow”, IMPRIMIS NJOF, LLC, a New Jersey limited liability company (“NJOF”), PARK COMPOUNDING, INC. (f/k/a ImprimisRx CA, Inc.), a California corporation (“CA”), IMPRIMISRX NJ, LLC, a New Jersey limited liability company (“NJ”), IMPRIMISRX, LLC, a Delaware limited liability company (“ImprimisRx”), HARROW IP, LLC, a Delaware limited liability company (“Harrow IP”) ETON PHARMA EQUITY, LLC, a Delaware limited liability company (“Eton Pharma Equity”), SURFACE PHARMA EQUITY, LLC, a Delaware limited liability company (“Surface Pharma Equity”), MELT PHARMA EQUITY, LLC, a Delaware limited liability company (“Melt Pharma Equity”), MAYFIELD PHARMA EQUITY, LLC, a Delaware limited liability company (“Mayfield Pharma Equity”), STOWE PHARMA EQUITY, LLC, a Delaware limited liability company (“Stowe Pharma Equity”), and RADLEY PHARMA EQUITY, LLC, a Delaware limited liability company (“Radley Pharma Equity”, and together with Harrow, NJOF, CA, NJ, ImprimisRx, Harrow IP, Eton Pharma Equity, Surface Pharma Equity, Melt Pharma Equity, Mayfield Pharma Equity, and Stowe Pharma Equity, individually and collectively, jointly and severally, “Grantor”) in favor of SWK FUNDING LLC in its capacity as collateral agent for the Lenders (as defined below) (together with its successors and assigns in such capacity, “Collateral Agent”). This Agreement amends and restates in its entirety that certain Intellectual Property Security Agreement, dated as of July 19, 2017, by Harrow, as Grantor, in favor of Collateral Agent (as amended, restated, supplemented, or otherwise modified from time to time prior to the date hereof, the “Original Agreement”).

RECITALS

A. Grantor has entered into a Loan and Security Agreement with certain financial institutions party thereto (the “Lenders”) and Collateral Agent, in its capacity as collateral agent for itself and the Lenders, dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the “Loan Agreement”). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (as defined in the Loan Agreement).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral shall not include (i) any lease, license, contract, property rights, joint venture interests, or agreement to which Grantor is a party or any of its rights or interests thereunder, in each case, if and only if, and solely to the extent that, the grant of a security interest therein shall constitute or result in a breach, termination, default, abandonment, unenforceability or invalidity thereunder or thereof (other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC of any relevant jurisdiction or any other applicable law or principles of equity); provided that immediately upon the time at which the consequences described in the foregoing clause shall no longer exist, the Collateral shall include, and Grantor shall be deemed to have granted a security interest in, all of Grantor's right, title and interest in such lease, license, contract, property rights, joint venture interests, or agreement; or (ii) any "intent-to-use" application for registration of a Trademark filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, prior to the filing of a "Statement of Use" pursuant to Section 1(d) of the Lanham Act or an "Amendment to Allege Use" pursuant to Section 1(c) of the Lanham Act with respect thereto, solely to the extent, if any, that, and solely during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Collateral Agent.

Grantor hereby authorizes Collateral Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Collateral Agent with

respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Collateral Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Collateral Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Collateral Agent's successors and assigns.

6. Governing Law. This Agreement has been negotiated and delivered to Collateral Agent in the State of New York, and shall have been accepted by Collateral Agent in the State of New York. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

7. Effect of Amendment and Restatement; No Novation. This Agreement is intended to and does completely amend and restate, without novation, the Original Agreement. This Agreement is not a novation and the terms and conditions of this Agreement shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. All security interests granted by each Grantor under the Original Agreement are hereby confirmed and ratified and shall continue to secure all Obligations under the Loan Agreement. Nothing in this Agreement is intended, or shall be construed, to constitute an accord and satisfaction of any Obligations under or in connection with the Loan Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of Collateral Agent's security interest (on behalf of itself and the Lenders) in, security titles to, or other liens on any Collateral for the Obligations.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

HARROW HEALTH INC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

IMPRIMIS NJDF, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

PARK COMPOUNDING, INC.

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

IMPRIMISRX NJ, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

IMPRIMISRX, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

HARROW IP, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

ETON PHARMA EQUITY, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

[Signature Page to A&R Intellectual Property Security Agreement]

SURFACE PHARMA EQUITY, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

MELT PHARMA EQUITY, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

MAYFIELD PHARMA EQUITY, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

RADLEY PHARMA EQUITY, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer


STOWE PHARMA EQUITY, LLC

By Andrew Boll
Name: Andrew Boll
Title: Chief Financial Officer

COLLATERAL AGENT:

SWK FUNDING LLC

By: SWK HOLDING CORPORATION,
its sole member

By: 
Name: Winston Black III
Title: Chief Executive Officer

[Signature Page to A&R Intellectual Property Security Agreement]

TRADEMARK
REEL: 006800 FRAME: 0949

EXHIBIT A

Copyrights

| Grantor | Title | Registration No. Registration Date |
|----------------|--------------|---------------------------------------|
| Harrow IP, LLC | DEFEAT IC. | VA0001987155 2015-08-20 |
| Harrow IP, LLC | SAY GOODBYE. | VA0001986245 2015-08-19 |
| Harrow IP, LLC | DROPPY. | VAu001299793 2017-03-29 |

EXHIBIT B**Patents**

| Grantor | Title | Application No. Application Date | (Publication No.) Patent No. Issue Date |
|----------------|--|-------------------------------------|---|
| Harrow IP, LLC | Pharmaceutical Formulations Of Tranexamic Acid And Their Use | 14325630 7/8/2014 | 9301936 4/5/2016 |
| Harrow IP, LLC | Epinephrine-Based Ophthalmic Compositions For Intraocular Administration And Methods For Fabricating Thereof | 14506120 10/3/2014 | (20150119440) |
| Harrow IP, LLC | Pharmaceutical Compositions Comprising Gels And Methods For Fabricating Thereof | 14719157 5/21/2015 | (20150335704) |
| Harrow IP, LLC | Pharmaceutical Compositions For Intraocular Administration And Methods For Fabricating Thereof | 14972822 12/17/2015 | (20160101118) |
| Harrow IP, LLC | Pharmaceutical Compositions For Intraocular Administration And Methods For Fabricating Thereof | 15057711 3/1/2016 | (20160175323) |
| Harrow IP, LLC | Pharmaceutical Compositions For Intraocular Administration And Methods For Fabricating Thereof | 15061488 3/4/2016 | (20160184323) |
| Harrow IP, LLC | Intraocular Lens Comprising Pharmaceutical Compositions And Methods For Fabricating Thereof | 15066731 3/10/2016 | 9814673 2017-11-14 |
| Harrow IP, LLC | Pharmaceutical Ophthalmic Compositions And Methods For Fabricating Thereof | 15148574 5/6/2016 | (20160243031) |
| Harrow IP, LLC | Pharmaceutical Compositions For Anesthesiological Applications | 15184768 6/16/2016 | 9918993 2018-03-20 |
| Harrow IP, LLC | Epinephrine-Based Ophthalmic Compositions For Intraocular Administration And Methods For Fabricating Thereof | 15241958 8/19/2016 | (20160354308) |
| Harrow IP, LLC | Epinephrine-Based Ophthalmic Compositions For Intraocular Administration And Methods For Fabricating Thereof | 15247524 8/25/2016 | (20170049721) |
| Harrow IP, LLC | Pharmaceutical formulations for treating kidney.. | 15383211 12/19/2016 | (20170172960) |
| Harrow IP, LLC | Pharmaceutical Compositions Comprising Gels And Methods For Fabricating Thereof | 15395830 12/30/2016 | (20170105931) |
| Harrow IP, LLC | Pharmaceutical Compositions Comprising Gels And Methods For Fabricating Thereof | 15399258 1/5/2017 | (20170112936) |
| Harrow IP, LLC | Curcumin-Based Pharmaceutical Compositions And Methods For Fabricating Thereof | 15653769 2017-07-19 | (20180028470) |
| Harrow IP, LLC | Pharmaceutical Ophthalmic Compositions And Methods For Fabricating Thereof | 15552450 2017-08-21 | (20190111045) |
| Harrow IP, LLC | Epinephrine-Based Ophthalmic Compositions For Intraocular Administration And Methods For Fabricating Thereof | 15685702 2017-08-24 | 10285957 2019-05-14 |
| Harrow IP, LLC | Pharmaceutical Formulations For Treating Glaucoma And Methods For Fabricating And Using Thereof | 15832169 2017-12-05 | (20180169092) |
| Harrow IP, LLC | Anti-Fungal Compositions For Treating Nails And Methods For Fabricating And Using Thereof | 16026542 2018-07-03 | <u>10426744</u> <u>10-01-19</u> |

| Grantor | Title | Application No. Application Date | (Publication No.) Patent No. Issue Date |
|----------------|--|--|---|
| Harrow IP, LLC | Pharmaceutical Compositions Of Tiopronin And Methods For Preparing Thereof | 16174954 2018-10-30 | (20190060266) |
| Harrow IP, LLC | Pharmaceutical Compositions For Intraocular Administration And Methods For Fabricating Thereof | 16209765 2018-12-04 | (20190105320) |
| Harrow IP, LLC | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | 16250450 2019-01-17 | (20190142841) |
| Harrow IP, LLC | Compositions of cholinesterase inhibitr + alpha-1-adrenergic antagonist | 62845061 2019-05-08 | |

EXHIBIT C

Trademarks

| Grantor | Mark | International Class(es) | Application No. Filing Date | Registration No. Registration Date |
|----------------|---|-------------------------|-----------------------------|-------------------------------------|
| Harrow IP, LLC |  | 5 | 87392566 30-MAR-2017 | 5470969 15-MAY-2018 |
| Harrow IP, LLC | BRIM-DOR | 5 | 88105741 05-SEP-2018 | <u>5747816</u> <u>05-07-2019</u> |
| Harrow IP, LLC | COMBINATION DROP THERAPY | 5 | 86758894 16-SEP-2015 | 5158156 07-MAR-2017 |
| Harrow IP, LLC | CORRECT COMPOUND | 44 | 87180522 22-SEP-2016 | 5293114 19-SEP-2017 |
| Harrow IP, LLC | DEFEAT IC | 41 | 86728843 18-AUG-2015 | 5025348 23-AUG-2016 |
| Harrow IP, LLC | DEX-MOXI | 5 | 86852608 17-DEC-2015 | 5131504 31-JAN-2017 |
| Harrow IP, LLC | DEX-MOXI-KETOR | 5 | 87351119 27-FEB-2017 | 5587077 16-OCT-2018 |
| Harrow IP, LLC | DROPLESS | 5 | 86694124 15-JUL-2015 | 5125985 17-JAN-2017 |
| Harrow IP, LLC | DROP-LESS | 5 | 86518153 29-JAN-2015 | 5423725 13-MAR-2018 |
| Harrow IP, LLC | DROPLESS CATARACT SURGERY | 5 | 86451161 11-NOV-2014 | 5018511 09-AUG-2016 |
| Harrow IP, LLC | DROPLESS CATARACT THERAPY | 5 | 86497090 07-JAN-2015 | 4978985 14-JUN-2016 |
| Harrow IP, LLC | DROPLESS THERAPY | 5 | 86497100 07-JAN-2015 | 4884290 12-JAN-2016 |
| Harrow IP, LLC | ED FREE | 5 | 86694135 15-JUL-2015 | 4976595 14-JUN-2016 |
| Harrow IP, LLC | ED FREE | 41 | 86730358 19-AUG-2015 | 4958892 17-MAY-2016 |
| Harrow IP, LLC | GATI-DEX | 5 | 87673958 06-NOV-2017 | 5562939 11-SEP-2018 |
| Harrow IP, LLC | GO DROPLESS | 5 | 86143553 13-DEC-2013 | 5022923 16-AUG-2016 |

| Grantor | Mark | International Class(es) | Application No. Filing Date | Registration No. Registration Date |
|----------------|---|-------------------------|-----------------------------|------------------------------------|
| Harrow IP, LLC |  | 5, 41 | 86760039 17-SEP-2015 | 4972265 07-JUN-2016 |
| Harrow IP, LLC | GODROPLESS | 41 | 86759927 17-SEP-2015 | 4950925 03-MAY-2016 |
| Harrow IP, LLC | HLA | 5 | 86627139 12-MAY-2015 | 4938331 12-APR-2016 |
| Harrow IP, LLC | IMPRIMIS | 5 | 86143561 13-DEC-2013 | 5100697 13-DEC-2016 |
| Harrow IP, LLC | IMPRIMIS | 44 | 86527529 06-FEB-2015 | 4890492 19-JAN-2016 |
| Harrow IP, LLC | IMPRIMIS CARES | 44 | 86867042 06-JAN-2016 | 5008088 26-JUL-2016 |
| Harrow IP, LLC | IMPRIMIS CARES! | 44 | 86867077 06-JAN-2016 | 5022193 16-AUG-2016 |
| Harrow IP, LLC | IMPRIMIS PHARMACEUTICALS | 44 | 86810634 05-NOV-2015 | 4978131 14-JUN-2016 |
| Harrow IP, LLC | IMPRIMISRX | 44 | 86527531 06-FEB-2015 | 4890493 19-JAN-2016 |
| Harrow IP, LLC | IV FREE | 41 | 86966512 06-APR-2016 | 5163172 14-MAR-2017 |
| Harrow IP, LLC |  | 5 | 87085396 27-JUN-2016 | 5198496 09-MAY-2017 |
| Harrow IP, LLC | KLARITY DROPS | 5 | 87649355 17-OCT-2017 | 5662585 22-JAN-2019 |
| Harrow IP, LLC | KLARITY-C DROPS | 5 | 87670016 02-NOV-2017 | 5681626 19-FEB-2019 |
| Harrow IP, LLC |  | 5 | 87053033 27-MAY-2016 | 5091225 29-NOV-2016 |
| Harrow IP, LLC | LESSDROPS | 5 | 86497791 07-JAN-2015 | 4884291 12-JAN-2016 |
| Harrow IP, LLC | LESSDROPS | 41 | 86758923 16-SEP-2015 | 4950904 03-MAY-2016 |
| Harrow IP, LLC | MELT | 5 | 87799283 15-FEB-2018 | |
| Harrow IP, LLC | MKO MELT | 5 | 86966404 06-APR-2016 | 5158235 07-MAR-2017 |

| Grantor | Mark | International Class(es) | Application No. Filing Date | Registration No. Registration Date |
|----------------|---|-------------------------|-----------------------------|------------------------------------|
| Harrow IP, LLC | PPS-DR | 5 | 86671228 23-JUN-2015 | 5134795 31-JAN-2017 |
| Harrow IP, LLC | PRED-BROM | 5 | 87731119 21-DEC-2017 | 5577593 02-OCT-2018 |
| Harrow IP, LLC | PRED-GATI | 5 | 87180492 22-SEP-2016 | 5342159 21-NOV-2017 |
| Harrow IP, LLC | PRED-GATI-BROM | 5 | 87329328 08-FEB-2017 | 5505056 26-JUN-2018 |
| Harrow IP, LLC | PRED-GATI-NEPAF | 5 | 87180506 22-SEP-2016 | 5342160 21-NOV-2017 |
| Harrow IP, LLC | PRED-KETOR | 5 | 86852556 17-DEC-2015 | 5117425 10-JAN-2017 |
| Harrow IP, LLC | PRED-MOXI | 5 | 86712793 03-AUG-2015 | 5039133 13-SEP-2016 |
| Harrow IP, LLC | PRED-MOXI-KETOR | 5 | 86852341 17-DEC-2015 | 5117424 10-JAN-2017 |
| Harrow IP, LLC | PRED-NEPAF | 5 | 87180514 22-SEP-2016 | 5342161 21-NOV-2017 |
| Harrow IP, LLC | SIMPLE DROPS | 41 | 87351103 27-FEB-2017 | 5716196 02-APR-2019 |
| Harrow IP, LLC | SIMPLE DROPS  | 5 | 87775093 29-JAN-2018 | 5688871 05-MAR-2019 |
| Harrow IP, LLC | SSP TECHNOLOGY | 5, 40 | 86530228 10-FEB-2015 | 4919401 15-MAR-2016 |
| Harrow IP, LLC | STERICHECK | 35 | 86698481 20-JUL-2015 | 5438639 03-APR-2018 |
| Harrow IP, LLC | TIM-BRIM-DOR | 5 | 87329891 09-FEB-2017 | 5505057 26-JUN-2018 |
| Harrow IP, LLC | TIM-BRIM-DOR-LAT | 5 | 87329905 09-FEB-2017 | 5505058 26-JUN-2018 |
| Harrow IP, LLC | TIM-DOR-LAT | 5 | 87345932 22-FEB-2017 | 5505062 26-JUN-2018 |
| Harrow IP, LLC | TIM-LAT | 5 | 87329876 09-FEB-2017 | 5542813 14-AUG-2018 |

| Grantor | Mark | International Class(es) | Application No. Filing Date | Registration No. Registration Date |
|----------------|---------------------------|-------------------------|--------------------------------|---------------------------------------|
| Harrow IP, LLC | TOTAL TEARS | 5 | 87546241 27-JUL-2017 | 5638938 25-DEC-2018 |
| Harrow IP, LLC | TOTAL TEARS TOTALTEARS | 5 | 87775062 29-JAN-2018 | 5565048 18-SEP-2018 |
| Harrow IP, LLC | TRI-MOXI | 5 | 86712769 03-AUG-2015 | 5034588 06-SEP-2016 |
| Harrow IP, LLC | TRIPLE DROP | 5 | 86561020 11-MAR-2015 | 5083870 15-NOV-2016 |

EXHIBIT D

Mask Works

N/A